561 related articles for article (PubMed ID: 26322474)
1. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.
Rahme K; Guo J; Holmes JD; O'Driscoll CM
Colloids Surf B Biointerfaces; 2015 Nov; 135():604-612. PubMed ID: 26322474
[TBL] [Abstract][Full Text] [Related]
2. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
Guo J; O'Driscoll CM; Holmes JD; Rahme K
Int J Pharm; 2016 Jul; 509(1-2):16-27. PubMed ID: 27188645
[TBL] [Abstract][Full Text] [Related]
3. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
4. Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles.
Kim HJ; Takemoto H; Yi Y; Zheng M; Maeda Y; Chaya H; Hayashi K; Mi P; Pittella F; Christie RJ; Toh K; Matsumoto Y; Nishiyama N; Miyata K; Kataoka K
ACS Nano; 2014 Sep; 8(9):8979-91. PubMed ID: 25133608
[TBL] [Abstract][Full Text] [Related]
5. Gold Nanoparticles Conjugated with Dendrigraft Poly-L-lysine and Folate-Targeted Poly(ethylene glycol) for siRNA Delivery to Prostate cancer.
Minassian G; Ghanem E; Hage RE; Rahme K
Nanotheranostics; 2023; 7(2):152-166. PubMed ID: 36793347
[TBL] [Abstract][Full Text] [Related]
6. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
7. Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery.
Xu CF; Zhang HB; Sun CY; Liu Y; Shen S; Yang XZ; Zhu YH; Wang J
Biomaterials; 2016 May; 88():48-59. PubMed ID: 26945455
[TBL] [Abstract][Full Text] [Related]
8. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
[TBL] [Abstract][Full Text] [Related]
9. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
10. Orthogonal analysis of functional gold nanoparticles for biomedical applications.
Tsai DH; Lu YF; DelRio FW; Cho TJ; Guha S; Zachariah MR; Zhang F; Allen A; Hackley VA
Anal Bioanal Chem; 2015 Nov; 407(28):8411-22. PubMed ID: 26362156
[TBL] [Abstract][Full Text] [Related]
11. Efficacious cellular codelivery of doxorubicin and EGFP siRNA mediated by the composition of PLGA and PEI protected gold nanoparticles.
Kumar K; Vulugundam G; Jaiswal PK; Shyamlal BRK; Chaudhary S
Bioorg Med Chem Lett; 2017 Sep; 27(18):4288-4293. PubMed ID: 28838699
[TBL] [Abstract][Full Text] [Related]
12. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.
Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S
Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715
[TBL] [Abstract][Full Text] [Related]
13. A comparison of gold nanoparticle surface co-functionalization approaches using Polyethylene Glycol (PEG) and the effect on stability, non-specific protein adsorption and internalization.
Harrison E; Nicol JR; Macias-Montero M; Burke GA; Coulter JA; Meenan BJ; Dixon D
Mater Sci Eng C Mater Biol Appl; 2016 May; 62():710-8. PubMed ID: 26952476
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
15. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
[TBL] [Abstract][Full Text] [Related]
16. Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
Rahme K; Guo J; Holmes JD
Methods Mol Biol; 2019; 1974():291-301. PubMed ID: 31099011
[TBL] [Abstract][Full Text] [Related]
17. Enhanced delivery of biodegradable mPEG-PLGA-PLL nanoparticles loading Cy3-labelled PDGF-BB siRNA by UTMD to rat retina.
DU J; Sun Y; Li FH; DU LF; Duan YR
J Biosci; 2017 Jun; 42(2):299-309. PubMed ID: 28569253
[TBL] [Abstract][Full Text] [Related]
18. Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles.
Yi Y; Kim HJ; Mi P; Zheng M; Takemoto H; Toh K; Kim BS; Hayashi K; Naito M; Matsumoto Y; Miyata K; Kataoka K
J Control Release; 2016 Dec; 244(Pt B):247-256. PubMed ID: 27590214
[TBL] [Abstract][Full Text] [Related]
19. The effect of ligand composition on the in vivo fate of multidentate poly(ethylene glycol) modified gold nanoparticles.
Liu X; Huang N; Wang H; Li H; Jin Q; Ji J
Biomaterials; 2013 Nov; 34(33):8370-81. PubMed ID: 23932246
[TBL] [Abstract][Full Text] [Related]
20. Gold nanostar-polymer hybrids for siRNA delivery: Polymer design towards colloidal stability and in vitro studies on breast cancer cells.
Sardo C; Bassi B; Craparo EF; Scialabba C; Cabrini E; Dacarro G; D'Agostino A; Taglietti A; Giammona G; Pallavicini P; Cavallaro G
Int J Pharm; 2017 Mar; 519(1-2):113-124. PubMed ID: 28093325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
